For research use only. Not for therapeutic Use.
Imazodan（Cat No.:I029242） is a type III phosphodiesterase (PDE) inhibitor with potential therapeutic applications in congestive heart failure (CHF) treatment. By inhibiting PDE, imazodan increases intracellular cyclic AMP levels, leading to positive inotropic and vasodilatory effects on cardiac muscle cells. These effects can enhance cardiac contractility and promote vasodilation, potentially improving heart function and relieving symptoms of CHF.
| Catalog Number | I029242 |
| CAS Number | 84243-58-3 |
| Synonyms | Imazodan |
| Molecular Formula | C13H12N4O |
| Purity | 98% |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Room Temperature |
| IUPAC Name | 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)- |
| InChI | InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18) |
| InChIKey | VXMYWVMXSWJFCV-UHFFFAOYSA-N |
| SMILES | O=C1CCC(=NN1)c2ccc(cc2)n3ccnc3 |
| Reference | 1. Goldberg AD, Nicklas J, Goldstein S. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. Am J Cardiol. 1991 Sep 1;68(6):631-6. doi: 10.1016/0002-9149(91)90356-p. PMID: 1715125. |
